- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 27th, 2005
Starpharma shares soared yesterday after the nanotechnology group confirmed that it had signed a strategic and potentially lucrative deal with The Dow Chemical Company.
Under the three-way deal, Starpharma's US-based subsidiary, Dendritic NanoTechnologies (DNT), will acquire Dow's extensive portfolio of patents covering dendrimer technology. It also gains the rights to revenue from Dow's already established licensing activities.
|Related News Press|
Nanometrics to Participate in the Citi 2015 Global Technology Conference August 26th, 2015
Multi-million pound project to use nanotechnology to improve safety September 4th, 2015
Magnetic wormhole connecting 2 regions of space created for the first time: The device could have applications in medicine, opening up ways to make MRIs more comfortable for patients September 4th, 2015
Making nanowires from protein and DNA September 3rd, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015